Related Experiment Video
Updated: Jul 26, 2026
07:01
Working Memory Training for Older Participants: A Control Group Training Regimen and Initial Intellectual Functioning Assessment
Published on: September 20, 2020
Exercise Intervention Associated with Cognitive Improvement in Alzheimer's Disease
Meng Ying Cui1, Yang Lin1, Ji Yao Sheng1
1Jilin Provincial Key Laboratory on Molecular and Chemical Genetic, The Second Hospital of Jilin University, 218 Ziqiang Street, Changchun 130041, China.
Neural Plasticity
|May 2, 2018
Summary
Exercise may slow cognitive decline in aging individuals at risk for Alzheimer's disease (AD). This non-pharmacological approach shows promise for mild cognitive impairment (MCI) and healthy aging, offering a cost-effective therapy for dementia prevention.
Area of Science:
- Neuroscience
- Gerontology
- Pharmacology
Background:
- Alzheimer's disease (AD) is a progressive neurodegenerative disorder causing cognitive and functional decline.
- Current pharmacotherapy for AD often involves clinical delays, particularly when cognitive deficits in episodic memory, working memory, and executive function are present.
- Mild cognitive impairment (MCI) represents a preclinical stage of AD where neuroplasticity may allow for reversal of neurodegeneration.
Purpose of the Study:
- To explore the potential of exercise intervention as a non-pharmacological therapy for cognitive decline in aging individuals.
- To investigate the efficacy of exercise in ameliorating cognitive impairment at different stages, including MCI and healthy aging at risk for AD.
- To establish a standard strategy for exercise intervention tailored to varying levels of cognitive decline.
Main Methods:
- Review of accumulating evidence on exercise intervention for cognitive impairment.
- Analysis of the role of neuroplasticity in reversing neurodegeneration during MCI.
- Exploration of cost-effective, non-pharmacological therapeutic strategies for dementia prevention.
Main Results:
- Accumulating evidence suggests exercise intervention can ameliorate cognitive impairment in aging populations.
- Early-stage exercise intervention in MCI and at-risk healthy aging individuals may slow cognitive decline.
- Exercise presents a promising, cost-effective non-pharmacological therapy for dementia.
Conclusions:
- Exercise intervention is a viable strategy to potentially slow cognitive impairment progression in aging individuals.
- Targeting MCI and at-risk healthy aging populations with exercise could be a key non-pharmacological approach to dementia prevention.
- Further development of standard exercise strategies is needed for different cognitive decline levels.
Related Concept Videos
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:30Cognitive Development During Adulthood
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...